For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of this treatment and Tafamidis meglumine represents a genuine advancement . These groundbreaking therapies stabilize the transthyretin protein, preventing its destructive build-up and reducing the impact of the disease . People are now expe